Description: Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types. EarlyCDT-Lung is a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. EarlyCDT-Lung test is being used in the randomized trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland Early Childhood Longitudinal Study (ECLS) of over 12,000 high-risk smokers. It is also developing the EarlyCDT tests for other cancers, which include in particular the liver and ovarian cancers. It has sold over 145,000 tests in the United States and the United Kingdom.
Home Page: www.oncimmune.com
ONC Technical Analysis
MediCity
Nottingham,
NG90 6BH
United Kingdom
Phone:
44 1157 840 500
Officers
| Name | Title |
|---|---|
| Dr. Adam Mark Hill Ph.D. | CEO & Director |
| Mr. Matthew Hall | Chief Financial Officer |
| Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP | Chief Scientific Officer |
| Ms. Cléa Rosenfeld | Head of Investor Relations |
| Mr. Ron Kirschner | Gen. Counsel & Company Sec. |
| Dr. James R. Jett M.D. | Chief Medical Officer of US |
| Mr. Maarten Brusse | Chief Commercial Officer of Asia |
| Mr. Shane Smith | Sr. VP of Market Access & Reimbursement Oncimmune (Usa) |
| Mr. Cameron Barnard | Chief Bus. Officer |
| Mr. Andrew Millet BA, FCA, MBA | Exec. |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 27.3224 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 49.2727 |
| Price-to-Sales TTM: | 8.6417 |
| IPO Date: | |
| Fiscal Year End: | May |
| Full Time Employees: | 0 |